TLPH— TALPHERA, INC.

MaterialsPharmaceuticals$74M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$28K	$0-100.0%	$651K	$0
Research and development	$6.0M-10.2%	$6.7M+21.1%	$5.5M+66.0%	$3.3M
Selling, general and administrative	$7.5M-12.4%	$8.5M-28.8%	$12.0M-29.5%	$17.0M
Total operating costs and expenses	$13.5M-11.4%	$15.3M-13.0%	$17.5M-30.7%	$25.3M
Loss from operations	-$13.5M+11.6%	-$15.3M+9.7%	-$16.9M+33.2%	-$25.3M
Interest income and other income, net	$436K-35.8%	$679K-52.0%	$1.4M+286.9%	$366K
Gain on sale of future payments	$0-100.0%	$1.2M	$0	—
(Loss) gain on change in fair value of warrant liability	-$1.3M-283.4%	$717K-86.5%	$5.3M	—
Non-cash interest expense on liability related to the sale of future payments	$0+100.0%	-$394K	$0	—
Total other income, net	-$879K-139.1%	$2.2M-65.9%	$6.6M-92.2%	$84.4M
Net loss from continuing operations	-$14.4M-10.5%	-$13.0M-26.4%	-$10.3M-117.4%	$59.1M
Net income from discontinued operations – See Note 3	$73K	$0+100.0%	-$8.1M+28.7%	-$11.4M
Net loss	-$14.3M-9.9%	-$13.0M+29.3%	-$18.4M-138.5%	$47.8M
Basic and diluted, continuing operations (in dollars per share)	-$0.34+32.0%	-$0.50+30.6%	-$0.72-109.9%	$7.27
Basic and diluted, discontinued operations (in dollars per share)	$0.00	$0.00+100.0%	-$0.57+63.0%	-$1.54
Basic and diluted loss per share (in dollars per share)	-$0.34+32.0%	-$0.50+61.2%	-$1.29-122.5%	$5.73
Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares)	$42410711.00+64.1%	$25845639.00+81.2%	$14263744.00+93.1%	$7385348.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.